SimonMed is integrating Optellum's U.S. Food and Drug Administration (FDA)-cleared lung cancer prediction AI into its existing lung nodule clinical workflow.
Under the partnership, eligible lung nodules identified on chest CT scans will automatically flow into Optellum's Lung Cancer Prediction (LCP) AI, which analyzes nodule characteristics and generates an AI-derived LCP score to assist in clinical decision-making, according to the companies. The integration builds on SimonMed's existing AI-enabled lung nodule program, powered by Infervision, which provides automated volumetric sizing and interval-growth tracking.
Every LCP score will be reviewed by a board-certified SimonMed radiologist before inclusion in the final report, the companies said. Once fully deployed, the workflow will cover SimonMed's network of more than 175 outpatient imaging centers across 10 states.
